Home / Issues / Issue #3
Psyche Insights Weekly · Issue #3

Two psilocybin applications reach the FDA, Slovenia opens the door to psilocybin trials, and what Europe's rules say about training psychedelic therapists

· Published by Psyche Vibes Ltd, London

Independent, evidence-first news on psychedelic-assisted therapy research, regulation and business, with the UK and Europe first. This is information, not medical advice. We do not promote using any controlled substance outside lawful clinical settings.

Compass has completed its psilocybin application to the US Food and Drug Administration, and Usona is reported to have filed one too. Neither filing changes the law in the UK or the EU, but they set the clock for everything that follows here. This issue covers the two weeks since Issue #2. Every claim links to its source, and our live approval tracker is updated.


🇺🇸 Two psilocybin applications at the FDA

  • Compass completes its COMP360 filing. On 9 November, London-founded Compass Pathways said it had completed its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression. It is based on two Phase 3 trials and a Phase 2b study that each met their primary endpoint, with more than 1,000 participants in total. Compass expects a US launch in the first half of 2027, subject to FDA approval (Compass, 9 Nov).
  • The review could be short. In its Q3 results on 3 November, Compass said its National Priority Voucher could shorten FDA review to one to two months, and reported $444 million in cash at the end of September (Compass Q3). Even after an approval, psilocybin would have to be rescheduled by the DEA and by states before it could be prescribed in the US (Drug Discovery Trends, 10 Nov).
  • Usona is reported to have filed first. Psychedelic Alpha reported on 2 November that the non-profit Usona Institute has completed its own application for psilocybin in major depressive disorder, a broader group than treatment-resistant depression. Usona did not comment. Like Compass, it holds a priority voucher, so the outlet says a first FDA decision on a psychedelic could come in late 2026 or very early 2027 (Psychedelic Alpha, 2 Nov). Usona has had Breakthrough Therapy designation for this programme since 2019 (Usona).

🇬🇧 UK: what the US filings do and don't change

  • Nothing changes in UK law yet. Psilocybin stays in Schedule 1. The Home Office said on 27 October that reconsidering its scheduling "would ordinarily follow" an MHRA assessment of a licence application (UK Parliament written answer 37245). We have not found an announced MHRA application from either company. COMP360 holds a UK Innovative Licensing and Access Pathway designation, according to Compass (our tracker).
  • New guide: training to work in this field. Our new explainer, Psychedelic therapist training in Europe, sets out what the rules say in Czechia, Switzerland, Germany and the UK, and compares four UK and European programmes on length, entry rules and published fees.

Read the rest free: subscribe

3 more sections in this issue. Subscribers get every issue in full, free, each week.

Subscribe free →
Already subscribed? The full issue is in your inbox. One email a week, unsubscribe any time, and we never sell your data.

Psyche Insights is an independent publication by Psyche Vibes Ltd, 71-75 Shelton Street, Covent Garden, London WC2H 9JQ. Nothing here is medical, legal or investment advice. If you're struggling, speak to your GP or call Samaritans on 116 123 (UK). Sponsorships are always labelled. Spotted an error? Email [email protected] and we'll correct it publicly.